(A–D, F–I) Androstadienone- and estratetraenol- induced visual gender judgment biases in the absence of drug treatment (A and F, adapted from Zhou et al., 2014 for comparison) and after the nasal administrations of 60 µg atosiban (B, G), 24 IU oxytocin (C, H), and 24 IU vasopressin (D, I) in heterosexual (Experiment 1, A–D) and homosexual (Experiment 2, F–I) men. Gender identification performances under the exposures of androstadienone, estratetraenol, and the carrier control are respectively fitted with sigmoidal curves (blue solid curves, red solid curves, and gray dashed curves, respectively). Insets show the androstadienone- and estratetraenol- induced proportional ‘male’ biases at the gender-neutral point of the point-light walkers (PLWs), that is, androstadienone- and estratetraenol- induced differences in the proportion of ‘male’ responses at Z = 0 relative to the carrier control condition. (E, J) Androstadienone- and estratetraenol- induced overall point of subjective equality (PSE) shifts with respect to the carrier control after the nasal administrations of 60 µg atosiban, 24 IU oxytocin (OT), and 24 IU vasopressin (VP) in heterosexual (E) and homosexual (J) men. A positive PSE shift indicates a feminine bias, that is, a bias toward perceiving the PLWs as more feminine, whereas a negative PSE shift indicates a masculine bias, that is, a bias toward perceiving the PLWs as more masculine. Dashed box: data from our earlier study (Zhou et al., 2014); error bars: SEMs adjusted for individual differences; *: p<0.05; **: p≤0.01; ***: p≤0.005.